Purchase Order 75N95020P00696
Award Date
9/30/20
Potential Completion Date
9/29/22
Potential Value
$299K
Funding Federal Agency
National Institute on Aging
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
QPS Austria GMBH
Ultimate Awardee
Not listed
NAICS Category
621511 - Medical Laboratories
PSC Category
Q301 - Reference Laboratory Testing
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Austria
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services' National Institutes of Health National Institute on Aging has awarded a $830,053.00 firm fixed price delivery order contract to QPS Austria GMBH, a contract research organization, to conduct experimental validation of candidate Alzheimer's disease treatments identified through multi-omics analyses. This delivery order is part of a larger indefinite delivery contract with QPS Austria GMBH to provide these services, with a potential total value...
<p>The National Institutes of Health National Institute on Aging, within the Department of Health and Human Services, awarded a $638,000 firm fixed price delivery order contract to QPS Austria GmbH. The contract is for experimental validation of candidate Alzheimer's disease treatments identified through multi-omics analyses. The period of performance is from June 1, 2022 through May 31, 2023, with all work to be conducted in Austria by QPS Austria GmbH as the prime contractor.</p>
This is a $199,812 firm fixed price purchase order awarded by the National Institutes of Health's (NIH) National Institute on Aging (NIA) to QPS Austria GMBH, a contract research organization. The contract is for in vivo efficacy studies of a candidate Alzheimer's treatment in a transgenic mouse model. This award is part of the NIA's Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study, which aims to identify FDA-approved drugs that may be repurposed as disease-modifying...
This is a $249,334 firm fixed-price purchase order awarded by the National Institute on Aging (NIA) to Scantox Neuro GMBH, a for-profit organization based in Austria. The contract supports pharmacodynamic and tolerability studies of candidate Alzheimer's disease (AD) drugs using a transgenic AD mouse model. This work builds on NIA's ongoing efforts under the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) and Experimental Validation of Candidate Alzheimer's Disease Treatments...
This is a firm fixed-price delivery order contract awarded by the National Institute on Aging (NIA), a civilian federal agency, to Scantox Neuro GMBH, a for-profit organization based in Austria. The contract, valued at $858,106.08, is for the experimental validation of candidate Alzheimer's disease treatments identified through multi-omics analyses. This work supports ongoing NIA research initiatives such as the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) and PREVENT-AD studies....
This is a firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Aging to the National University of Singapore. The $169,830 contract is for testing the efficacy of candidate Alzheimer's disease treatments in rescuing impaired hippocampal synaptic plasticity. This is part of the NIH's Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study, which is testing approximately 20 FDA-approved drugs to...
This is a firm-fixed-price purchase order award to Alamar Biosciences, Inc. by the National Institute on Aging (NIA), a civilian agency, for $247,000.00. The contract is for providing proteomic analysis services, including the NULISAseq CNS Disease Panel 120 assay, next-generation sequencing, and bioinformatic support for 1,118 plasma samples. The purpose is to identify biomarkers that can be used to classify and stage Alzheimer's disease. This award is not associated with a set-aside and is the...
The National Institutes of Health's National Institute on Aging awarded The Johns Hopkins University a $16,450.30 firm fixed price purchase order contract to provide testing and laboratory services for immunophenotyping cells in cerebrospinal fluid of Alzheimer's disease patients. The work will be performed in Baltimore, Maryland over a one year period from January 1, 2024 through December 31, 2024. This contract supports the National Institute on Aging's research efforts to better understand...
The National Institute on Aging, a component of the National Institutes of Health within the Department of Health and Human Services, awarded a firm-fixed price purchase order valued at $3.4 million to New York Stem Cell Foundation Inc. The contract calls for the contractor to generate up to 200 induced pluripotent stem cell lines derived from fresh whole blood or peripheral blood mononuclear cells of patients with Alzheimer's disease or related dementias. The cell lines must be collected by...
The National Institute on Aging (NIA), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), awarded an $852,000 firm fixed price delivery order contract to The Bioteam, Inc. (Bioteam) under the company's Multiple Award Schedule contract vehicle. Bioteam will perform an Alzheimer's Disease (AD) and Alzheimer's Disease-Related Dementias (ADRD) Data Ecosystem Landscape Assessment for NIA through November 15, 2023 from its place of performance...